In the wake of a recent safety scare in a confirmatory trial of its antibody-drug conjugate Zynlonta, ADC Therapeutics is tightening its belt in an effort to get the most out of its cancer med. On ...

Three times as many deaths in the study arm versus the control arm in a trial of ADC Therapeutics' Zynlonta have raised questions about the antibody-drug conjugate (ADC), which has been on the market ...

Former Vice President Atiku Abubakar has emerged as the presidential candidate of the African Democratic Congress for the 2027 general election. The result was announced on Wednesday night at the ...

With traditional ADCs now fulfilling their potential to reshape the standard of oncology care, the bioconjugate community is doubling down on differentiation to ensure the next wave of ADCs delivers ...

You may have noticed an officer standing just behind the President of India at official events, state visits, or ceremonial functions. That officer holds a very important role as an Aide-de-Camp (ADC) ...

As speculations intensify over who emerges as the presidential candidate of the African Democratic Congress ahead of the 2027 general elections, the party’s leadership has insisted its immediate ...

After five years of unprecedented momentum, the ADC field now finds itself at an interesting inflection point. With more programs in development and greater industry prioritization than ever before, ...

The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects. There is still more work to be done to refine ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

As a creative individual, Jordan Tassiello has a track record of achievements in founding her own business and working with large companies on writing, editing, design, content creation and campaigns.

Merck & Co. has shown off data on its ROR1-directed antibody-drug conjugate (ADC), trumpeting a 100% complete response rate but also reporting safety signals that informed the decision to take the low ...